Alkali-stable kappa light chain binding separation matrices
By using covalently coupled alkali-stable κ light chain binding ligand and porous carrier in the affinity chromatography separation matrix, the instability problem of the separation matrix in the prior art in alkali cleaning procedures is solved, achieving efficient Impurity removal and improvement of biopharmaceutical production efficiency.
Patent Information
- Application Number
- CN202380027454.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-16
- Filing Date
- 2023-03-08
- Publication Date
- 2024-11-08
AI Technical Summary
The existing affinity chromatographic separation matrix is unstable in alkaline cleaning procedures and is difficult to effectively remove impurities and contaminants. Especially for protein L matrix, it has low tolerance, which affects the production efficiency and cost control of biopharmaceuticals.
Develop an isolated matrix containing a covalently coupled κ light chain binding ligand using a base-stabilized L domain of the Great Fingoldella protein, bound to a porous carrier with specific dry solid weight and volume weighted median Diameter and stability is enhanced by crosslinking polymer particles, preferably a plurality of base-stabilized protein L domains are included.
It improves the stability and binding capacity of the separation matrix in an alkaline environment, can maintain efficient cleaning in high concentrations of NaOH, extends the service life of the separation matrix, reduces production costs, and improves the production efficiency of biopharmaceuticals.
Smart Images

Figure CN118922247A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomolecule separation. More specifically, the present invention relates to a separation matrix for affinity chromatography and separation of biomolecules such as immunoglobulins and immunoglobulin fractions based on the presence of kappa light chains. The present invention also relates to a method of using the separation matrix. Background Art
[0002] Immunoglobulins and immunoglobulin fragments represent the most common biopharmaceutical products produced or developed worldwide. The high commercial demand and therefore value for this specific therapeutic market has led to a focus on pharmaceutical companies to control the associated costs while maximizing the productivity of their respective production processes.
[0003] Affinity chromatography, typically on a matrix containing Staphylococcus Protein A or its variants, is commonly used as one of the key steps in the purification of intact immunoglobulin molecules. The highly selective binding of Protein A to the Fc chains of immunoglobulins provides a general procedure with very high clearance of impurities and contaminants.
[0004] For immunoglobulin fragments or antibody fragments lacking Fc chains but having 1, 3 or 4 subclass kappa light chains, such as Fab, single-chain variable fragment (scFv), bispecific T-cell engagers (BiTE), domain antibodies, etc., a matrix (B) comprising protein L derived from Finegoldia magna (formerly known as Peptoscoccus Magnus) L J. Biol. Chem. 264, 19740-19746, 1989; W Kastem et al.: J. Biol. Chem. 267, 12820-12825, 1992; B HK Nilson et al.: J. Biol. Chem. 267, 2234-2239, 1992; and U.S. Pat. No. 6,822,075) show great promise as a purification platform that provides the desired high selectivity.
[0005] Protein L matrices are commercially available, for example as TM Capto TML, and can be used to separate proteins containing κ light chains, such as complete antibodies, Fab fragments, scFv fragments, domain antibodies, etc. About 75% of antibodies produced by healthy people have κ light chains, and about 90% of therapeutic monoclonal antibodies and antibody fragments contain κ light chains (Carter, P., Lazar, G. Next generation antibody drugs: pursuit of the'high-hanging fruit'. Nat Rev Drug Discov 17, 197–223 (2018). https: / / doi.org / 10.1038 / nrd.2017.227).
[0006] Any bioprocess chromatography application requires comprehensive attention to the clear removal of impurities and / or contaminants. Such impurities and / or contaminants can be, for example, uneluted molecules adsorbed to the stationary phase or matrix during the chromatographic procedure, such as undesirable biomolecules or microorganisms, including, for example, proteins, carbohydrates, lipids, bacteria and viruses. Removal of such impurities and / or contaminants from the matrix is usually carried out after the first elution of the desired product, so that the matrix can be regenerated before subsequent use. This removal usually includes a procedure called cleaning in place (CIP), in which a reagent capable of inactivating impurities or eluting impurities from the stationary phase is used. A class of such reagents commonly used with chromatographic media is an alkaline solution, which is passed over the matrix. At present, the most widely used cleaning and disinfecting agent is NaOH, and depending on the degree and nature of contamination and impurities, it is desirable to use NaOH in a concentration ranging from 0.05M to, for example, 1M. However, compared to, for example, protein A, protein L is a protein that is quite sensitive to alkali and only tolerates up to about 15mM NaOH in several cycles. This means that to ensure adequate cleaning, additional, less-than-ideal cleaning solutions, such as urea or guanidine salts, may have to be used.
[0007] Therefore, there remains a need in the art to obtain separation matrices containing Protein L-derived ligands having improved stability towards alkaline cleaning procedures. Summary of the invention
[0008] According to a first aspect, the present disclosure provides a separation matrix comprising at least 12 mg / ml of a κ light chain binding ligand covalently coupled to a porous support, wherein the κ light chain binding ligand comprises, consists essentially of, or consists of a multimer of an alkali-stable Feingolda macrocarpon (formerly known as Peptostreptococcus macrocarpon) protein L domain; and the porous support comprises polymer particles having a dry solid weight (DW) of 50-200 mg / ml. W ), volume-weighted median diameter (D50v) of 30-100 μm.
[0009] The separation matrix according to the above may comprise at least 14 mg / ml κ light chain binding ligand, such as at least 14.5 mg / ml, at least 15 mg / ml, at least 15.5 mg / ml, at least 16 mg / ml, at least 16.5 mg / ml, at least 17 mg / ml, at least 17.5 mg / ml, at least 18 mg / ml, at least 18.5 mg / ml or at least 19 mg / ml κ light chain binding ligand.
[0010] D of porous support W It may be 50-150 mg / ml, 50-120 mg / ml, 50-100 mg / ml, 50-90 mg / ml, 60-80 mg / ml or 60-75 mg / ml, such as at least 63 mg / ml, or at least 65 mg / ml, or at least 70 mg / ml.
[0011] The volume weighted median diameter (D50v) of the porous support may be 35-90 μm, 40-80 μm, 50-70 μm, 55-70 μm, 55-67 μm, 58-70 μm or 58-67 μm, such as at least 60 μm or at least 62 μm.
[0012] The separation matrix according to the above may have a Kd value of 0.6-0.95, such as a Kd value of 0.7-0.9, or a Kd value of 0.6-0.8, such as a Kd value of about 0.67, or a Kd value of about 0.72, or a Kd value of about 0.75, measured by reversed phase size exclusion chromatography using dextran of Mw 110 kDa as probe molecule.
[0013] The polymer particles in the separation matrix according to above may be cross-linked.
[0014] In the separation matrix according to the above, at least two of the alkali-stable protein L domains may be selected from functional variants of the B1 domain, B2 domain, B3 domain, B4 domain, B5 domain, C2 domain, C3 domain, C4 domain and D1 domain of protein L of Peptostreptococcus magna (formerly known as Peptostreptococcus magna), wherein the positions corresponding to positions 10 and 45 in the alignment of the B2 domain (SEQ ID NO 1) are histidine, and the position corresponding to position 60 in the alignment of the B2 domain (SEQ ID NO 1) is tyrosine or glutamine. The at least two alkali-stable protein L domains may preferably be selected from the B2 domain, B3 domain, B4 domain, C2 domain, C3 domain, C4 domain and D1 domain.
[0015] The at least two alkali-stable protein L domains may have at least 90%, 95% or 98% sequence identity or 77.5% sequence similarity with any one of the amino acid sequences SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18 or SEQ ID NO 19, as determined by a BLOSUM matrix of 75, with a gap open penalty of 12 and a gap extension penalty of 3, wherein the positions corresponding to positions 10 and 45 in the alignment and the position corresponding to position 60 in the alignment are invariant.
[0016] The separation matrix according to above may comprise three, four, five, six, seven, eight or nine alkali-stable protein L domains. The separation matrix according to above may preferably comprise four, five or six alkali-stable protein L domains.
[0017] The ligand may additionally comprise a coupling element, which is one or more cysteine residues, one or more lysine residues or one or more histidine residues at the C-terminus of the ligand. Preferably, the ligand comprises one or more cysteine residues at the C-terminus of the ligand.
[0018] Preferably, the separation matrix according to the above has a 10% breakthrough dynamic binding capacity for IgG at a 4 min residence time of at least 55 mg / ml. Preferably, the separation matrix according to the above has a 10% breakthrough dynamic binding capacity for IgG at a 6 min residence time of at least 70 mg / ml. Preferably, the separation matrix according to the above has a 10% breakthrough dynamic binding capacity for IgG at a 10 min residence time of at least 80 mg / ml.
[0019] Preferably, the IgG capacity of the separation matrix according to the above after incubation for 24 h in 0.1 M NaOH at 22 + / - 2°C is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before incubation. Preferably, the IgG capacity of the separation matrix according to any of the above after incubation for 32 h in 0.3 M NaOH at 22 + / - 2°C is at least 90% of the IgG capacity before incubation. Preferably, the IgG capacity of the separation matrix according to the above after incubation for 12 h in 0.5 M NaOH at 22 + / - 2°C is at least 95%, or at least 93% of the IgG capacity before incubation.
[0020] According to another aspect, the present disclosure provides a method for isolating a protein containing a kappa light chain, the method comprising the steps of:
[0021] a) contacting a liquid sample comprising a protein containing a kappa light chain with a separation matrix,
[0022] b) washing the separation matrix with a washing liquid or a combination of washing liquids,
[0023] c) eluting the kappa light chain-containing protein from the separation matrix using an eluent, and
[0024] d) cleaning the separation matrix with a cleaning solution,
[0025] wherein the IgG capacity of the separation matrix after incubation in 0.1 M NaOH at 22+ / -2°C for 24 h is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before incubation.
[0026] According to yet another aspect, the present disclosure provides a method for isolating a bispecific antibody, the method comprising the following steps:
[0027] a) contacting a liquid sample comprising a protein containing a kappa light chain with a separation matrix,
[0028] b) washing the separation matrix with a washing liquid or a combination of washing liquids,
[0029] c) eluting the kappa light chain-containing protein from the separation matrix using an eluent and at a reduced pH,
[0030] d) cleaning the separation matrix with a cleaning solution,
[0031] wherein the IgG capacity of the separation matrix after incubation in 0.1 M NaOH at 22+ / -2°C for 24 h is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before incubation.
[0032] Reducing pH in any of the above methods can be done by using a pH gradient. Alternatively, reducing pH in any of the above methods can be done in a stepwise manner. In any of the above methods, reducing pH can be about 5.5 to about 2, such as about 5 to about 2, about 4.5 to about 2, or about 4 to about 2.
[0033] The cleaning solution may contain 0.01-1.0 M NaOH or KOH, such as 0.05-1.0 M or 0.05-0.1 M, or 0.05-0.3 M, or 0.05-0.5 NaOH or KOH.
[0034] The eluent may contain at least one anionic species selected from the group consisting of acetate, citrate, glycine, succinate, phosphate and formate.
[0035] Steps a)-d) in any of the above methods may be repeated at least 10 times, such as at least 50 times or 50-200 times.
[0036] The separation matrix used in any of the above methods may be a separation matrix according to the first aspect or any variation thereof as disclosed above.
[0037] Additionally, in yet another aspect, provided herein is a chromatography column comprising the separation matrix according to the first aspect and any variant thereof as disclosed above.
[0038] According to another aspect, there is provided herein the use of a chromatography column according to above in any of the methods disclosed above. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1: Correlation between ligand density and base stability. Figure 1a Shown is the relationship between ligand density and remaining capacity after 112 CIP cycles with 0.1 M NaOH in the case of trastuzumab. Figure 1b Shown is the DBC at 10% breakthrough (Qb10%) for different ligand densities using Fab fragments. Figure 1c The relative remaining Qb10% for selected ligands and trastuzumab are shown.
[0040] Figure 2 : Explanation of the obtained QB10 model with respect to the ligand density and the Kd and Dw of the porous support.
[0041] Figure 3: Alkali stability from accelerated alkaline stability studies comparing commercially available products and prototypes of different ligand densities. Figure 3a The results for two prototypes and Capto with different ligand densities are shown. TML, Qb10% at 4 min residence time after 100 cycles of CIP with 100 mM NaOH in the presence of trastuzumab. Figure 3b The results for two prototypes and Capto with different ligand densities are shown. TM L, Relative remaining Qb10% after 100 cycles of CIP with 100 mM NaOH. Figure 3c The relative remaining QB10 of the prototype is shown for 0.1 M NaOH, 0.3 M NaOH, and 0.5 M NaOH.
[0042] Figure 4: Qb10% vs. residence time for the prototype compared to the following commercially available products: AF-r Protein L-650F(Tosoh)、Capto TM L(Cytiva TM ) and KanCap TM L(Kaneka). Figure 4a Qb10% at different residence times with trastuzumab is shown. Figure 4b Qb10% at different residence times with Fab fragments is shown. Figure 4c Qb10% at different residence times in the presence of dAb is shown.
[0043] Figure 5: Results from chromatography with the prototype separation matrix. Figure 5a Shown is the chromatogram of a 50 ml sample of bsAb01 with step elution at pH 3.4 and pH 3.1 with an elution volume of 5 CV and an elution flow rate of 1 ml / min. Figure 5b An overview of the elution peaks and the fractions analyzed by MS is shown. Peak 1, Peak 2 and Peak 3 are labeled with numbers 1 to 3. The fractions analyzed by MS are marked with asterisks.
[0044] Figure 6: Figure 5b MS (mass spectrometry) analysis of peaks 1, 2 and 3. Figure 6a Shown from Figure 5b Results of non-reduced MS analysis of Peak 2. Figure 6b Shown from Figure 5b Results of non-reduced MS analysis of Peak 3.
[0045] Figure 7 : Results from chromatography with the prototype separation matrix. Figure 7 Shown is the chromatogram of a 10 ml sample of BsAb01, pH gradient elution chromatogram at pH 5.5-2.5, 40 CV, 4 min RT. Fractions analyzed by MS are marked with asterisks.
[0046] Figure 8: Prototype and Capto TM Overlay of size exclusion chromatograms of L. Figure 8a An overlay of the chromatograms of the eluate is shown. Figure 8b An overlay of the chromatograms of the flow-through (FT) fractions is shown.
[0047] definition
[0048] The terms "antibody" and "immunoglobulin" are used interchangeably herein and refer to an antigen binding protein having a basic four polypeptide chain structure consisting of two heavy chains (H) and two light chains (L), which are stabilized by interchain or intrachain disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains: CH1, CH2 and CH3. Each light chain consists of a light chain variable region (VL) and a light chain constant region. The light chain constant region consists of one domain CL. There are two types of light chains in humans, kappa chains and lambda chains. The term should be understood to include any antibody, including but not limited to monoclonal antibodies and bispecific antibodies, as well as antibody fragments, fusion proteins comprising antibodies or antibody fragments, and conjugates comprising antibodies or antibody fragments.
[0049] The terms "κ light chain binding polypeptide" and "κ light chain binding protein" are used herein to refer to a κ light chain that is capable of binding to subclass 1, 3, or 4 of an antibody (also known as a V κI 、V κIII and V κIV , such as in BH K Nilson et al.: J. Biol. Chem. 267, 2234-2239, 1992), and includes, for example, protein L and any variants, fragments or fusion proteins thereof that have retained the binding properties.
[0050] The term "κ light chain-containing protein" is used as a synonym for "immunoglobulin κ light chain-containing protein" and refers herein to a protein containing 1, 3 or 4 subclass κ light chains (also called V κI 、V κIII and V κIV , such as in BH K Nilson et al.: J. Biol. Chem. 267, 102234-2239, 1992), and includes any complete antibody, antibody fragment, fusion protein, conjugate or recombinant protein containing 1, 3 or 4 subclass kappa light chains.
[0051] The term "mAb" stands for monoclonal antibody.
[0052] The term "Fab" stands for an antigen-binding fragment from an immunoglobulin comprising a kappa light chain or a lambda light chain.
[0053] The term "bispecific antibody" represents an antibody that can bind to two different types of antigens or two different epitopes on the same antigen. Similarly, a trispecific antibody represents an antibody that can bind to three different types of antigens or three different epitopes on the same antigen.
[0054] "DBC" means dynamic binding capacity and is the binding capacity in a packed affinity chromatography column under operating conditions, i.e., during sample application. The DBC of a chromatography resin is the amount of target protein that binds to the resin under given flow conditions before significant breakthrough of unbound protein occurs. DBC is determined by loading a sample containing a known concentration of the target protein and monitoring the flow-through. Before the unbound protein flows through the column, the protein will bind to the resin to a certain inflection point.
[0055] DBC can be determined on the breakthrough curve at the loss of, for example, 10% protein. This is referred to as the Qb10% value, or simply Qb10%. The sample is applied to the chromatographic resin column during a specific residence time, and the dynamic binding capacity of each resin is calculated at 10% protein breakthrough (i.e., the amount of the target sample loaded onto the column until the concentration of the target sample in the column effluent is 10% of the target sample concentration in the liquid sample). If the dynamic binding capacity of each resin is calculated at 80% breakthrough capacity, this is referred to as the Qb80% value.
[0056] Kd is the value of the fraction of pore volume available to probe molecules of a specific size. Herein, Kd is measured by reversed phase size exclusion chromatography, for example, according to the method described in Gel Filtration Principles and Methods, Pharmacia LKB Biotechnology 1991, pp. 6-15 13, wherein a dextran of Mw 110 kDa is used as a probe molecule.
[0057] D50v is the value of the average particle size exceeding 50% by volume of the particle population.
[0058] As used herein, the term "liquid sample" refers to a liquid containing at least one target substance that is sought to be purified from other substances that also exist. The liquid sample can be, for example, an aqueous solution, an organic solvent system, or an aqueous / organic solvent mixture or solution. The source liquid is typically a complex mixture or solution containing many biomolecules (such as proteins, antibodies, hormones, and viruses), small molecules (such as salts, sugars, lipids, etc.) and even particulate matter. Although the typical source liquid of biological origin can be used as an aqueous solution or suspension, it can also contain organic solvents for earlier separation steps such as solvent precipitation, extraction, etc. The example of a liquid sample that can contain valuable biological substances that are suitable for purification by various embodiments of the present invention includes, but is not limited to, culture supernatant from a bioreactor, homogenized cell suspensions, blood plasma, plasma fractions, and milk. Alternatively, the liquid sample can be referred to as "clarified cell culture feed" or "CCF".
[0059] "Buffer" is a substance that, due to its presence in a solution, increases the amount of acid or base that must be added to cause a unit pH change. Buffer solutions resist changes in pH through the action of their acid-base conjugate components. Buffer solutions used with biological reagents are generally capable of maintaining a constant concentration of hydrogen ions so that the pH of the solution is within the physiological range. The term "physiological pH" refers to the pH of mammalian blood (i.e., 7.38 or about 7.4). Therefore, the physiological pH range is about 7.2 to 7.6. Traditional buffer components include, but are not limited to, organic and inorganic salts, acids and bases. Exemplary buffers for purifying biomolecules (e.g., protein molecules) include zwitterions or "Good" buffers, see, for example, Good et al. (1966) Biochemistry 5:467 and Good and Izawa (1972) Methods Enzymol.24:62.
[0060] "Equilibration buffer" is a buffer used to prepare binding reagents, solid phases, or both, for loading the source solution containing the target protein. The equilibrium buffer is preferably isotonic and generally has a pH in the range of about 6 to about 8. "Loading buffer" is a buffer used to load the source solution or liquid sample containing the protein containing the binding region and impurities onto the solid phase on which the binding reagent is immobilized. Typically, the equilibrium buffer and the loading buffer are the same.
[0061] As used herein, "washing liquid" or "washing buffer" refers herein to a liquid used to remove impurities from the chromatography resin bound to the target substance. More than one washing liquid can be used sequentially, for example, successive washing liquids with different properties such as pH, conductivity, solvent concentration, etc., which are designed to dissociate and remove different types of impurities that are non-specifically bound to the chromatography resin.
[0062] "Eluent" or "elution buffer" are used interchangeably herein and refer herein to a liquid used to dissociate the target substance from the chromatography resin, thereby eluting the protein containing the binding region from the immobilized binding agent after washing with one or more washing liquids. The eluent is used to dissociate the target substance without irreversibly denaturing it. Typical eluents are well known in the field of chromatography and may have different pHs (typically, lower pH), higher concentrations of salts, free affinity ligands or the like, or other substances that promote the dissociation of the target substance from the chromatography resin. "Elution conditions" refer to process conditions applied to a chromatography resin bound to a target substance to cause the target substance to dissociate from the chromatography resin, such as contacting the chromatography resin bound to the target substance with an eluent or elution buffer to produce such dissociation.
[0063] Preferably, the elution buffer has a low pH, thereby disrupting the interaction between the kappa light chain binding separation matrix and the target protein. Preferably, the pH of the low pH elution buffer is in the range of about 2 to about 5, most preferably in the range of about 3 to about 4. Examples of buffers that control the pH within this range include glycine, phosphate, acetate and citrate buffers, and combinations of these. Preferred such buffers are citrate and acetate buffers, most preferably sodium citrate or sodium acetate buffers.
[0064] The cleaning solution can be an acidic solution or an alkaline solution for removing resin residues after eluting the target substance. For example, precipitated proteins, hydrophobic proteins, nucleic acids, endotoxins and viruses can be removed by the cleaning solution. Most commonly, alkaline solutions are used for this purpose.
[0065] Cleaning in place (CIP) is an important process for the efficient use of chromatography columns. In order to maximize the number of cycles that a column can be reused, a cleaning procedure is required that effectively removes impurities without damaging the chromatography resin.
[0066] "HCP" stands for host cell protein.
[0067] As used herein, the terms "comprises", "comprising", "containing", "having" and the like may mean "includes", "including" and the like; "consisting essentially of" or "consists essentially" are open terms that allow for the existence of content other than the content as long as the basic or novel features of the content are not changed by the existence of content other than the content, but exclude prior art implementations. DETAILED DESCRIPTION
[0068] The inventors aimed to invent a separation matrix containing a ligand derived from protein L which has an improved stability towards alkaline cleaning procedures while maintaining satisfactory binding capacity and efficiency in terms of flow properties in a chromatographic setting and which is preferably superior to currently commercially available separation matrices.
[0069] According to one aspect, this object has been achieved by providing a separation matrix comprising at least 12 mg / ml of a κ light chain binding ligand covalently coupled to a porous support, wherein the κ light chain binding ligand comprises, consists essentially of, or consists of a polymer of an alkali-stable Peptostreptococcus major (formerly known as Peptostreptococcus major) protein L domain; and the porous support comprises polymer particles having a dry solid weight (Dw) of 50-200 mg / ml and a volume-weighted median diameter (D50v) of 30-100 μm.
[0070] The κ light chain binding ligand included in the separation matrix of the present invention comprises a polymer of the large Fingoldeella protein L domain that is stable to alkali, is basically composed of it, or is composed of it. The protein L domain can be any functional protein L derived domain, as long as it is alkali-stable. The protein L domain is selected from the functional variants of B1 domain, B2 domain, B3 domain, B4 domain, B5 domain, C2 domain, C3 domain, C4 domain and D1 domain, wherein the position corresponding to the position 10 and 45 in the B2 domain (SEQ ID NO 1) in the comparison is histidine, and the position corresponding to the position 60 in the B2 wt domain (SEQ ID NO 1) in the comparison is tyrosine or glutamine. Therefore, the above-mentioned position corresponding to the position 10,45 and 60 in the B2wt domain (SEQ ID NO 1) is immutable in the functional protein L domain.
[0071] SEQ ID NO:1 (wt B2)
[0072] PKEEVTIKANLIYADGKTQTAEFKGTFEEAAAEAYRYADALKKDNGEYTVDVADKGYTLNIKFAGKEKTPEE
[0073] Examples of such functional protein L domains may be:
[0074] SEQ ID NO: 2 (B2: N10H, N45H, N60Y mutations)
[0075] PKEEVTIKAHLIYADGKTQTAEFKGTFEEAAAEAYRYADALKKDHGEYTVDVADKGYTLYIKFAGKEKTPEE
[0076] SEQ ID NO:3(B2:N10H、N45H、N60Q function)
[0077] PKEEVTIKAHLIYADGKTQTAEFKGTFEEAAAEAYRYADALKKDHGEYTVDVADKGYTLQIKFAGKEKTPEE
[0078] SEQ ID NO:4(B3:N10H、N45H、N60Y extension)
[0079] PKEEVTIKAH LIYADGKTQT AEFKGTFEEA TAEAYRYADL LAKEHGKYTV DVADKGYTLYIKFAGKEKTP EE
[0080] SEQ ID NO:5(B3:N10H、N45H、N60Q function)
[0081] PKEEVTIKAH LIYADGKTQT AEFKGTFEEA TAEAYRYADLAKEHGKYTV DVADKGYTLQIKFAGKEKTP EE
[0082] SEQ ID NO:6(B1:N10H、N45H、N60Y range)
[0083] SEEEVTIKAHLIFANGSTQTAEFKGTFEKATSEAYAYADTLKKDHGEYTVDVADKGYTLYIKFAGKEKTPEE
[0084] SEQ ID NO:7(B1:N10H、N45H、N60Q group)
[0085] SEEEVTIKAHLIFANGSTQTAEFKGTFEKATSEAYAYADTLKKDHGEYTVDVADKGYTLQIKFAGKEKTPEE
[0086] SEQ ID NO:8(B4:N10H、N45H、N60Y range)
[0087] PKEEVTIKAHLIYADGKTQTAEFKGTFAEATAEAYRYADLAKEHGKYTADLEDGGYTIYIRFAGKKVDEKPEE
[0088] SEQ ID NO:9 (B4: N10H, N45H, N60Q mutations)
[0089] PKEEVTIKAHLIYADGKTQTAEFKGTFAEATAEAYRYADLLAKEHGKYTADLEDGGYTIQIRFAGKKVDEKPEE
[0090] SEQ ID NO 10 (B5: N9H, N44H, N59Y mutations)
[0091] KEQVTIKEH
[0092] IYFEDGTVQTATFKGTFAEATAEAYRYADLLSKEHGKYTADLEDG
[0093] GYTIQIRFAGKEEPEE
[0094] SEQ ID NO 11 (B5: N9H, N44H, N59Q mutations)
[0095] KEQVTIKEHIYFEDGTVQTATFKGTFAEATAEAYRYADLLSKEHGKYTADLEDGGYTIQIRFAGKEEPEE
[0096] SEQ ID NO 12 (C2b N57Y: N10H, N45H, N60Y mutations)
[0097] PKEEVTIKVHLIFADGKTQTAEFKGTFEEATAKAYAYADLLAKEHGEYTADLEDGGYTIYIKFAGKETPETPEE
[0098] SEQ ID NO 13 (C2b N57Y: N10H, N45H, N60Q mutations)
[0099] PKEEVTIKVHLIFADGKTQTAEFKGTFEEATAKAYAYADLLAKEHGEYTADLEDGGYTIQIKFAGKETPETPEE
[0100] SEQ ID NO 14 (C3b N39D, N57Y: N10H, N45H, N60Y mutations)
[0101] PKEEVTIKVHLIFADGKIQTAEFKGTFEEATAKAYAYADLLAKEHGEYTADLEDGGYTIYIKFAGKETPETPEE
[0102] SEQ ID NO 15 (C3b N39D, N57Y: N10H, N45H, N60Q mutation)
[0103] PKEEVTIKVHLIFADGKIQTAEFKGTFEEATAKAYAYADLLAKEHGEYTADLEDGGYTIQIKFAGKETPETPEE
[0104] SEQ ID NO:16 (C4: N10H, N45H, N60Y mutation)
[0105] PKEEVTIKVHLIFADGKTQTAEFKGTFEEATAEAYRYADLLA KVHGEYTADLEDGGYTIYIKFAGKEQPGENPG
[0106] SEQ ID NO:17 (C4: N10H, N45H, N60Q mutation)
[0107] PKEEVTIKVHLIFADGKTQTAEFKGTFEEATAEAYRYADLLA KVHGEYTADLEDGGYTIQIKFAGKEQPGENPG
[0108] SEQ ID NO:18 (D1: N10H, N45H, N60Y mutation)
[0109] PKEEVTIKAHLIFADGKTQTAEFKGTFEEATAEAYRYADLLAKVHGEYTADLEDGGYTIYIKFAGKEQPGEN
[0110] SEQ ID NO:19 (D1: N10H, N45H, N60Q mutation)
[0111] PKEEVTIKAHLIFADGKTQTAEFKGTFEEATAEAYRYADLLAKVHGEYTADLEDGGYTIQIKFAGKEQPGEN
[0112] Preferably, the protein L domain is selected from the group consisting of a B3 domain, a C2 domain, a C3 domain and a D-domain, wherein the positions corresponding to positions 10 and 45 in the alignment of the B2 wt domain (SEQ ID NO 1) are histidines, and the position corresponding to position 60 in the alignment of the B2 wt domain (SEQ ID NO 1) is tyrosine or glutamine. The above positions corresponding to positions 10, 45 and 60 in the B2 wt domain (SEQ ID NO 1) are invariant within the functional protein L domain.
[0113] The remaining positions in the L domain of this functional protein can be varied, as long as the three-dimensional structure is not changed compared to the B2 wt domain (SEQ ID NO 1), and at least the kappa light chain binding capacity is retained and it is alkali stable compared to the B2 wt domain (SEQ ID NO 1). The variation can be a conservative amino acid substitution for an amino acid with similar or identical charge, hydrophobicity, etc., and a skilled person can determine what this variation of an amino acid can be.
[0114] The protein L domain may have at least 90%, 95% or 98% sequence identity or 77.5% sequence similarity to any of the amino acid sequences SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18 or SEQ ID NO 19, as determined by a BLOSUM matrix of 75, with a gap open penalty of 12 and a gap extension penalty of 3.
[0115] The functional protein L domain can be a truncated sequence. For example, the position corresponding to position 1-4 in the B2 wt domain (SEQ ID NO 1) can be deleted. For example, the position corresponding to the position after position 65 in the B2 wt domain (SEQ ID NO 1) can be deleted.
[0116] SEQ ID NO:20 (B1_trunc, N6H, N41H, N56Y mutations)
[0117] VTIKAHLIFANGSTQTAEFKGTFEKATSEAYAYADTLKKDHG EYTVDVADKGYTLYIKFAG
[0118] SEQ ID NO:21 (B1_trunc, N6H, N41H, N56Q mutation)
[0119] VTIKAHLIFANGSTQTAEFKGTFEKATSEAYAYADTLKKDHG EYTVDVADKGYTLQIKFAG
[0120] SEQ ID NO:22 (B2_trunc, N6H, N41H, N56Y mutation)
[0121] VTIKAHLIYADGKTQTAEFKGTFEEAAAEAYRYADALKKDH GEYTVDVADKGYTLYIKFAG
[0122] SEQ ID NO:23 (B2_trunc, N6H, N41H, N56Q mutation)
[0123] VTIKAHLIYADGKTQTAEFKGTFEEAAAEAYRYADALKKDH GEYTVDVADKGYTLQIKFAG
[0124] SEQ ID NO:24 (B3_trunc, N6H, N41H, N56Y mutation)
[0125] VTIKAHLIYADGKTQTAEFKGTFEEATAEAYRYADLLAKEHG KYTVDVADKGYTLYIKFAG
[0126] SEQ ID NO:25 (B3_trunc, N6H, N41H, N56Q mutation)
[0127] VTIKAHLIYADGKTQTAEFKGTFEEATAEAYRYADLLAKEHG KYTVDVADKGYTLQIKFAG
[0128] SEQ ID NO:26 (B4_trunc, N6H, N41H, N56Y mutation)
[0129] VTIKAHLIYADGKTQTAEFKGTFAEATAEAYRYADLLAKEHG KYTADLEDGGYTIYIRFAG
[0130] SEQ ID NO:27 (B4_trunc, N6H, N41H, N56Q mutation)
[0131] VTIKAHLIYADGKTQTAEFKGTFAEATAEAYRYADLLAKEHG KYTADLEDGGYTIQIRFAG
[0132] SEQ ID NO:28 (B5_trunc, N6H, N41H, N56Y mutation)
[0133] VTIKEHIYFEDGTVQTATFKGTFAEATAEAYRYADLLSKEHG KYTADLEDGGYTIYIRFAG
[0134] SEQ ID NO:29 (B5_trunc, N6H, N41H, N56Q mutation)
[0135] VTIKEHIYFEDGTVQTATFKGTFAEATAEAYRYADLLSKEHG KYTADLEDGGYTIQIRFAG
[0136] SEQ ID NO:30 (C2b N57Y_trunc, N6H, N41H, N56Y mutation)
[0137] VTIKVHLIFADGKTQTAEFKGTFEEATAKAYAYADLLAKEHG EYTADLEDGGYTIYIKFAG
[0138] SEQ ID NO:31 (C2b N57Y_trunc, N6H, N41H, N56Q mutation)
[0139] VTIKVHLIFADGKTQTAEFKGTFEEATAKAYAYADLLAKEHG EYTADLEDGGYTIQIKFAG
[0140] SEQ ID NO:32 (C3b N39D, N57Y trunc, N6H, N41H, N56Y mutation)
[0141] VTIKVHLIFADGKIQTAEFKGTFEEATAKAYAYADLLAKEHG EYTADLEDGGYTIYIKFAG
[0142] SEQ ID NO:33 (C3b N39D, N57Y_trunc, N6H, N41H, N56Q mutation)
[0143] VTIKVHLIFADGKIQTAEFKGTFEEATAKAYAYADLLAKEHG EYTADLEDGGYTIQIKFAG
[0144] SEQ ID NO:34 (C4_trunc, N6H, N41H, N56Y mutation)
[0145] VTIKVHLIFADGKTQTAEFKGTFEEATAEAYRYADLLAKVHG EYTADLEDGGYTIYIKFAG
[0146] SEQ ID NO:35 (C4_trunc, N6H, N41H, N56Q mutation)
[0147] VTIKVHLIFADGKTQTAEFKGTFEEATAEAYRYADLLAKVHG EYTADLEDGGYTIQIKFAG
[0148] SEQ ID NO:36 (D1_trunc, N6H, N41H, N56Y mutation)
[0149] VTIKAHLIFADGKTQTAEFKGTFEEATAEAYRYADLLAKVHG EYTADLEDGGYTIYIKFAG
[0150] SEQ ID NO:37 (D1_trunc, N6H, N41H, N56Q mutation)
[0151] VTIKAHLIFADGKTQTAEFKGTFEEATAEAYRYADLLAKVHG EYTADLEDGGYTIQIKFAG
[0152] The protein L domain can have at least 90%, 95% or 98% sequence identity or 77.5% sequence similarity to any of the amino acid sequences SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36 or SEQ ID NO:37, as determined by a BLOSUM matrix of 75, with a gap opening penalty of 12 and a gap extension penalty of 3.
[0153] As can be seen above, the C2 domain and C3 domain contain additional mutations. The C2 domain scaffold contains an additional N57Y mutation and is designated herein as C2b. The C3 domain scaffold contains additional N39D and N57Y mutations and is designated herein as C3b.
[0154] As specified above, the κ light chain binding ligand included in the separation matrix comprises a polymer of an alkali-stabilized protein L domain, is essentially composed of it, or is composed of it. The polymer can include two, three, four, five, six, seven, eight or nine alkali-stabilized protein L domains. In alternative statements, the polymer can be a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer or nonamer. Preferably, the part comprises four, five, six or seven alkali-stabilized protein L domains, such as five or six alkali-stabilized protein L domains.
[0155] The polymer may further comprise a linker, a spacer or additional amino acids. The additional amino acids may, for example, originate from the cloning process of the ligand or constitute residues from a cleavage signaling sequence.
[0156] As specified above, the separation matrix comprises at least 12 mg / ml κ light chain binding ligand. Preferably, the separation matrix comprises at least 14 mg / ml κ light chain binding ligand, such as at least 14.5 mg / ml, at least 15 mg / ml, at least 15.5 mg / ml, at least 16 mg / ml, at least 16.5 mg / ml, at least 17 mg / ml, at least 17.5 mg / ml, at least 18 mg / ml, at least 18.5 mg / ml or at least 19 mg / ml κ light chain binding ligand. Figure 1a The correlation between ligand density and alkaline stability in terms of % remaining capacity of the separation matrix for trastuzumab is shown. Figure 1b The correlation between ligand density and Qb10% for Fab is shown. Figure 1a and Figure 1b It is clear that a ligand density of at least 12 mg / ml is beneficial for both alkaline stability and Qb10%.
[0157] Additionally, as shown in the examples below, these preferred ligand densities provide improved Qb10% as well as improved alkaline stability compared to existing products on the market. Figure 3a and Figure 3b Further explanation in.
[0158] The amount of coupled polypeptide / polymer can be controlled by the concentration of the polypeptide / polymer used in the coupling process, the coupling conditions used and / or the pore structure of the carrier used. As a general rule, the absolute binding capacity of the matrix increases with the amount of coupled polypeptide / polymer, at least reaching the point where the pore becomes significantly shrunk by the coupled polypeptide / polymer. The relative binding capacity of each mg of coupled polypeptide / polymer will decrease under high coupling levels, thereby producing the best cost-effectiveness within the range specified above.
[0159] The ligand may comprise a coupling element, which is one or more cysteine residues, one or more lysine residues, or one or more histidine residues at the C-terminus of the ligand. Preferably, the ligand may comprise one or more cysteine residues at the C-terminus of the ligand.
[0160] One or more coupling elements can be directly connected to the C- or N-terminus, or it / they can be connected via a linker comprising up to 15 amino acids, such as 1-5, 1-10 or 5-10 amino acids. This extension should preferably also be sufficiently stable in an alkaline environment so as not to impair the properties of the mutant ligand. For this purpose, it is advantageous if the extension does not contain asparagine. If the extension does not contain glutamine, it may be additionally advantageous. The advantage of having a C- or N-terminal cysteine is that, as described above, the end point coupling of the protein can be achieved by the reaction of cysteine thiols with the electrophilic groups on the carrier. This provides excellent mobility of coupled proteins, which is important for binding capacity.
[0161] The ligand or polymer can be coupled to the carrier via a thioether bond. The method for carrying out this coupling is well known in the art, and is easily carried out by those skilled in the art using standard techniques and equipment. The thioether bond is flexible and stable, and is generally suitable for affinity chromatography. In particular, when the thioether bond is via a terminal or near-terminal cysteine residue on a ligand or polymer, the mobility of the coupled ligand / polymer is enhanced, which provides improved binding capacity and binding kinetics. In some embodiments, the ligand / polymer is coupled via C-terminal cysteine. This allows the effective coupling of cysteine thiol with electrophilic groups on the carrier, such as epoxy groups, halohydrin groups, etc., to produce thioether bridge coupling. The ligand / polymer can be, for example, attached via a single point, for example, via a single cysteine or by directed multipoint attachment, using, for example, multiple lysines or other coupling groups to couple near the end of the polypeptide / polymer.
[0162] The solid support of matrix according to the present invention can be any suitable well-known type. Conventional affinity separation matrix is usually organic in nature, and is based on the polymer that hydrophilic surface is exposed to the aqueous medium used, that is, hydroxyl (-OH), carboxyl (-COOH), formamide (-CONH2, possibly in the form of N-replacement), amino (-NH2, possibly in the form of replacement), oligomeric or polyethylene oxide groups are exposed to its outside, and if present, also exposed on the inner surface. The solid support should be porous. Porosity can be expressed as Kav or Kd value (the fraction of the pore volume available for probe molecules of a specific size), which is measured by reversed-phase size exclusion chromatography, for example, according to Gel Filtration Principles and Methods, Pharmacia LKB Biotechnology 1991, the method described in 6-15 pages 13. According to definition, both Kd and Kav values are always within the range of 0-1. In one embodiment, the porous carrier has a Kd value of 0.6-0.95, such as a Kd value of 0.7-0.90, or a Kd value of 0.6-0.8, as measured with a dextran of Mw 110 kDa as a probe molecule. The porous carrier may preferably have a Kd value of about 0.67. The porous carrier may preferably have a Kd value of about 0.72. The porous carrier may preferably have a Kd value of about 0.75.
[0163] The higher the Kd value, the larger the pores in the porous support, and the larger the fraction of the internal volume of the beads that can be accessed by solute molecules (such as biomolecules, such as immunoglobulins). Those skilled in the art know this and can calculate the Kd of the porous support as described above. In the case of the preferred larger pores as described above, a larger amount of ligand is coupled to the porous support. In addition, in the case of larger pores such as those described above, proteins containing kappa light chains can also approach the ligands in the pores. Therefore, a larger binding capacity is achieved.
[0164] Multimeric ligands such as pentamers or hexamers give higher DBCs than lower order multimeric ligands such as tetramers or lower order multimeric ligands. This effect is especially true on solid supports with high Kd of 0.7-0.9.
[0165] In certain embodiments, the carrier comprises a polyhydroxy polymer, such as a polysaccharide. Examples of polysaccharides include, for example, dextran, starch, cellulose, pullulan, agar, agarose, etc. Polysaccharides are inherently hydrophilic, have a low degree of nonspecific interactions, they provide a high content of reactive (activatable) hydroxyl groups, and they are generally stable to alkaline cleaning solutions used in bioprocessing.
[0166] In some embodiments, the carrier comprises agar or agarose. The carrier used in the present invention can be easily prepared according to standard methods such as reverse suspension gelation (S Hjerten: Biochim Biophys Acta 79 (2), 393-398 (1964)). Alternatively, the base matrix is a commercially available product, such as SEPHAROSE TM FF(Cytiva TM ) are cross-linked agarose beads sold by . In one embodiment, which is particularly advantageous for large-scale separations, the support is adjusted to increase its rigidity, thereby making the matrix more suitable for high flow rates, using the methods described in US6602990 or US7396467, which are incorporated herein by reference in their entirety.
[0167] In certain embodiments, carrier, such as polysaccharide or agarose carrier, is cross-linked, such as cross-linked with hydroxyalkyl ether. The cross-linking agent reagent producing this cross-linking can be, for example, an epihalohydrin such as epichlorohydrin, a diepoxide such as butanediol diglycidyl ether, an allylation agent such as allyl halide or allyl glycidyl ether. Cross-linking is beneficial to the rigidity of the carrier and improves chemical stability. Hydroxyalkyl ether cross-linking is alkali-stabilized, and can not cause significant non-specific adsorption.
[0168] Alternatively, the solid support is based on synthetic polymers such as polyvinyl alcohol, polyhydroxyalkyl acrylates, polyhydroxyalkyl methacrylates, polyacrylamide, polymethacrylamide, etc. In the case of hydrophobic polymers, such as matrices based on divinyl and monovinyl substituted benzenes, the surface of the matrix is usually hydrophilized to expose the hydrophilic groups as defined above to the surrounding aqueous liquid. Such polymers are easily prepared according to standard methods, see for example "Styrenebased polymer supports developed by suspension polymerization" (R Arshady:Chimica e L'Industria 70 (9), 70-75 (1988)). Alternatively, commercially available products such as SOURCE TM (Cytiva TM ). In another alternative, the solid support according to the invention comprises a support of an inorganic nature, such as silicon dioxide, zirconium oxide, etc. In another alternative, the support particles are magnetic. An example of such support particles is a polysaccharide or synthetic polymer bead, which comprises, for example, magnetite particles, so that the beads can be used for magnetic batch separation.
[0169] The separation matrix is preferably in a porous bead or particle form. The matrix in bead or particle form can be used as a packed bed or in a suspended form. Suspended forms include those called expanded beds and pure suspensions, in which particles or beads move freely. In the case of packed beds and expanded beds, the separation procedure usually follows a conventional chromatography with a concentration gradient. In the case of a pure suspension, a batch mode will be used. Preferably, the separation matrix according to the above is filled in a chromatographic column.
[0170] Resins designed for large-scale chromatography and bioprocessing may typically have a D50V of typically 30 μm to 100 μm and a DW of 50 mg / mL to 200 mg / mL.
[0171] In a large scale column of 20 cm bed height with back pressure < 3 bar and bed volume > 3 L, the flow rate should preferably be about 250-500 cm / h. A person skilled in the art will be able to calculate the flow rate in a column of another size, height and volume and will then be able to adjust the settings accordingly.
[0172] The porous carrier in the form of beads or particles according to the present disclosure has a dry solid weight (Dw) of 50-200 mg / ml, such as 50-150 mg / ml, 50-120 mg / ml, 50-100 mg / ml, 50-90 mg / ml, 60-80 mg / ml or 60-75 mg / ml. Preferably, Dw is at least 63 mg / ml, or at least 65 mg / ml. Dw can be at least 70 mg / ml.
[0173] The porous support in bead or particle form may have a volume weighted median diameter (D50v) of 30-100. According to the present disclosure, D50v is preferably 35-90 μm, 40-80 μm or 50-70 μm, such as 55-70 μm, 55-67 μm, 58-70 μm or 58-67 μm. D50v may be, for example, at least 60 μm, or at least 62 μm.
[0174] The combination of the above ranges of Dw and d50v allows a high DBC to be achieved. In particular, the combination of the above ranges of Dw and d50v with the above ligand density allows a high Qb10% to be achieved, such as Figure 2 This DBC can be achieved with flow rates and back pressures as disclosed above that are still relevant for large-scale chromatography.
[0175] Figure 2 Contour plots of the prototype model at three different ligand densities are shown. It is evident from these plots that the upper right corner of the window will result in lower binding capacity. This is especially true where high ligand density is obtained.
[0176] The alkaline stability of the matrix can be evaluated by measuring the kappa light chain binding capacity before and after incubation in an alkaline solution at a specified temperature, such as 22 + / - 2 ° C, using, for example, a specific protein containing kappa light chains or polyclonal human IgG. The incubation can be, for example, repeated 15 min cycles in 0.1 M NaOH, such as 100, 200 or 300 cycles. After 100 15 min incubation cycles in 0.1 M NaOH at 22 + / - 2 ° C, the binding capacity of the matrix can be at least 80% of the binding capacity before incubation, such as at least 85%, at least 90% or at least 95%. Alternatively, incubation can be repeated 4 h cycles in 0.1 M NaOH, such as 6 cycles, giving a total incubation time of 24 h. After a total incubation time of 24 h min in 0.1 M NaOH at 22 + / - 2 ° C, the binding capacity of the matrix can be at least 80% of the binding capacity before incubation, such as at least 85%, at least 90% or at least 95%.
[0177] As shown in the examples below, the separation matrix according to the invention provides improved alkaline stability compared to commercially available protein L ligand resins. Figure 4a. According to the separation matrix above, the 10% penetration dynamic binding capacity of IgG at a 4min residence time is at least 55mg / ml. In addition, the separation matrix above has a 10% penetration dynamic binding capacity (Qb10%) of at least 70mg / ml at a 6min residence time for IgG. In addition, the separation matrix above has a 10% penetration dynamic binding capacity (Qb10%) of at least 80mg / ml at a 10min residence time for IgG.
[0178] According to another aspect, the present invention provides a method for isolating a protein containing a kappa light chain, the method comprising the following steps:
[0179] a) contacting a liquid sample comprising a protein containing a kappa light chain with a separation matrix,
[0180] b) washing the separation matrix with a washing liquid or a combination of washing liquids,
[0181] c) eluting the kappa light chain-containing protein from the separation matrix using an eluent, and
[0182] d) cleaning the separation matrix with a cleaning solution,
[0183] wherein the IgG capacity of the separation matrix after incubation in 0.1 M NaOH at 22+ / -2°C for 24 h is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before incubation.
[0184] According to one embodiment, a separation matrix as disclosed above is used in the method. Figure 8a As can be seen in the figure, the method for isolating a protein containing a kappa light chain according to the present invention provides for complete capture of the kappa light chain (VL) from CCF. Figure 8b As shown, there was no detectable VL in the flow-through fraction.
[0185] Elution can be performed using any suitable eluent for eluting from a protein L separation matrix. The eluent can be, for example, a solution or buffer at pH 4 or lower, such as pH 2.5-4 or 2.8-3.5. The elution buffer or elution buffer gradient can contain at least one mono-, di- or trifunctional carboxylic acid or a salt of such a carboxylic acid. The elution buffer or elution buffer gradient can contain at least one anionic species selected from acetate, citrate, glycine, succinate, phosphate and formate.
[0186] The generation of bispecific antibodies or IgG molecules is difficult due to the pairing of light chain and heavy chain, and therefore the variable domains (VL; VH) therein may be messy. The pairing of two different light chains and two different heavy chains may cause a large amount of mispairings, because usually only a specific asymmetric combination is desired, and the multiple combinations achieved will be non-functional or unwanted molecules, such as monospecific homodimers. Therefore, there is an increasing need for improved tools and methods for separating bispecific antibodies from monospecific antibodies and separating mispaired bispecific antibodies from correctly matched bispecific antibodies. This can be accomplished by separation based on the different light chains contained in the bispecific antibodies.
[0187] According to yet another aspect, provided herein is a method for isolating a bispecific antibody, the method comprising the following steps:
[0188] a) contacting a liquid sample comprising a protein containing a kappa light chain with a separation matrix,
[0189] b) washing the separation matrix with a washing liquid or a combination of washing liquids,
[0190] c) eluting the kappa light chain-containing protein from the separation matrix using an eluent and at a reduced pH, and
[0191] d) cleaning the separation matrix with a cleaning solution,
[0192] wherein the IgG capacity of the separation matrix after incubation in 0.1 M NaOH at 22+ / -2°C for 24 h is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before incubation.
[0193] According to one embodiment, a separation matrix as disclosed above is used in the method.
[0194] The above method can also be used to isolate trispecific antibodies.
[0195] The pH can be lowered by using a pH gradient. Alternatively, the pH can be lowered in a stepwise manner, similar to a gradient, using buffer solutions of different pH. The pH range during elution can be about 5.5 to about 2, such as about 5 to about 2, about 4.5 to about 2, or about 4 to about 2. Except for the pH, the eluent in the separation method is as disclosed above for the separation method.
[0196] This approach enables the separation of bispecific antibodies from monospecific antibodies or mismatched antibodies based on the presence of a kappa light chain. Monoclonal antibodies have two identical kappa light chains. Bispecific antibodies can be designed to contain two different kappa light chains. Figure 5- Figure 7The results of the method disclosed above are shown, wherein Figures 5 and 6 show the results of stepwise reduction of pH, and Figure 7 Results for a pH gradient used to decrease the pH are shown.
[0197] Any antibody that does not contain a kappa light chain, such as an antibody that contains two lambda light chains, will not bind to the separation matrix and will therefore be present in the effluent stream during step a) or will be washed away during step b). Any antibody that has at least one kappa light chain will bind to the separation matrix. Upon elution, antibodies that have only one kappa light chain will elute before antibodies that have two kappa light chains. This is Figure 5b and Figure 7 This is illustrated by schematic images of the corresponding antibodies and the locations where they are eluted or present in the flow-through.
[0198] By using a separation matrix as disclosed above that binds to κ light chains of subclass 1, 3 or 4, antibodies or antibody fragments comprising one or two κ light chains of subclass 2 can also be separated from antibodies or antibody fragments comprising one or two κ light chains of subclass 1, 3 or 4. By the same principle as described above, antibodies comprising two κ light chains of subclass 2, or one κ light chain of subclass 2 and a λ light chain will not bind to the separation matrix and will therefore be present in the effluent stream during step a) or will be washed away during step b). Antibodies having one κ light chain of subclass 2 and one κ light chain of any of subclasses 1, 3 or 4 will elute before antibodies having two κ light chains of any of subclasses 1, 3 and 4.
[0199] By lowering the pH in a stepwise manner during the elution step, e.g. Figure 5b As shown, three distinct peaks were formed. MS analysis of the eluate showed that the eluate from peak 1 contained λ light chain dimers, peak 2 contained dimers containing κ light chains and λ light chains, and peak 3 contained κ light chain dimers, see Figure 7 By lowering the pH in a pH gradient, only two peaks were observed. MS analysis of the eluate (data not shown) indicated that the first peak contained dimers containing kappa light chains and lambda light chains, and the second peak contained kappa light chain dimers.
[0200] The above method may further include the following steps: before step a), providing the affinity separation matrix as described above, and providing a liquid sample solution containing a protein containing a κ light chain and at least one other substance as a liquid sample. The method may further include the step of equilibrating the separation matrix with an equilibration buffer before adding the liquid sample.
[0201] The washing solution is typically a buffer solution similar or identical to the equilibrium buffer. Typically more than one washing solution is used. For example, a first washing solution may have a high salt content and a neutral pH, followed by a second washing solution that is salt-free and has a lower pH. Using a high salt content in the washing solution will improve the removal of impurities.
[0202] The liquid sample comprising a protein containing a kappa light chain and at least one other substance may contain host cell proteins (HCP), such as Chinese hamster ovary (CHO) cells, E. coli or yeast cell proteins. The content of CHO cells and E. coli proteins can be conveniently determined by immunoassays for these proteins, such as CHO HCP or E. coli HCP ELISA kits from Cygnus Technologies. Host cell proteins or CHO cell / E. coli / yeast proteins can be desorbed during step b).
[0203] The above method may also comprise, after step c), the step of recovering the eluate and optionally subjecting the eluate to a further separation step, for example by anion or cation exchange chromatography, multimodal chromatography and / or hydrophobic interaction chromatography. Suitable compositions of liquid samples, wash solutions and eluents as well as general conditions for carrying out the separation are well known in the art of affinity chromatography and in particular in the art of protein L chromatography.
[0204] The cleaning solution may preferably be alkaline, such as a pH of 12-14. Such solutions provide effective cleaning of the matrix, particularly at the upper end of the interval. The cleaning solution may comprise 0.01-1.0 M NaOH or KOH, such as 0.05-1.0, or 0.05-0.5, or 0.05-0.3, or 0.05-0.1 M NaOH or KOH. The high stability of the separation matrix of the present invention enables the use of such relatively alkaline solutions.
[0205] The IgG capacity of the separation matrix according to above after incubation for 24 h at 22+ / -2°C in 0.1 M NaOH is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before incubation.
[0206] The IgG capacity of the separation matrix after cleaning in 0.3 M NaOH at 22 + / - 2° C. for 130 cycles (contact time of 15 min per cycle) is at least about 90% of the IgG capacity before incubation. In an alternative formulation, the IgG capacity of the separation matrix after incubation in 0.3 M NaOH at 22 + / - 2° C. for 32 h is at least about 90% of the IgG capacity before incubation.
[0207] The IgG capacity of the separation matrix after cleaning in 0.5 M NaOH at 22 + / - 2°C for 50 cycles (contact time of 15 min per cycle) is at least 95%, or at least 93%, of the IgG capacity before incubation. In alternative terms, the IgG capacity of the separation matrix after incubation in 0.5 M NaOH at 22 + / - 2°C for 12 h is at least 95%, or at least 93% of the IgG capacity before incubation.
[0208] Thus, the separation matrices of the present disclosure can withstand cleaning with higher concentrations of alkaline solutions than are typically used for separation matrices based on Protein L ligand.
[0209] The cleaning of the separation matrix is preferably a CIP process (cleaning in place), which is a process well known to the person skilled in the art.
[0210] Steps a)-d) may be repeated at least 10 times, such as at least 50 times or 50-200 times. This is important for process economy, since the substrate can be reused multiple times. Figure 1c and FIG. 3 , where the separation matrix according to the above also maintains a high Qb10% after 100+ CIP cycles.
[0211] The high capacity of the separation matrix of the present invention provides a productivity advantage in biomanufacturing. Improved alkaline stability brings a more robust method and a long resin life, which increases the overall method economy. Therefore, the separation matrix of the present invention brings a significantly improved method economy of the separation step. Compared with other commercially available products, it also increases the value of key process parameters.
[0212] Experimental Section
[0213] Ligand characterization
[0214] Example 1 - Affinity testing of ligands - Biacore
[0215] Protein L variants were immobilized on a CM5 chip (Cytiva TM , Sweden) (see Biacore SensorSurface Handbook,
[0216] https: / / cdn.cytivalifesciences.com / dmm3bwsv3 / AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=16475).
[0217] EDC / NHS was used to activate the CM5 surface in both flow cells at a flow rate of 10 μl / min for 420 s, followed by a system wash (not sensor surface) with ethanolamine. Variants in immobilization buffer were injected onto flow cell 2 and immobilized onto the activated CM5 surface. Ethanolamine was injected onto both flow cells at a flow rate of 10 μl / min for 420 s to deactivate the surface.
[0218] Solution:
[0219] EDC 0.4M in water 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
[0220] NHS 0.1M N-Hydroxysuccinimide in water
[0221] Ethanolamine 1M Ethanolamine-HCl pH 8.5
[0222] Ligand is usually 10 to 50 μg / mL in immobilization buffer
[0223]
[0224] The protein L variants were then evaluated for their binding and apparent affinity to IgG (Gammanorm). The following assay conditions were used:
[0225] Analytes: Analytes were run in HBS-EP+ (Universal running buffer; 0.1 M HEPES, 1.5 M NaCl, 0.03 M EDTA and 0.5% v / v surfactant P20; from Cytiva TM )
[0226] Analyte concentration: 0.026, 0.053, 0.106, 0.2125, 0.425, 0.85, 1.7, 3.4 μM
[0227] Regeneration: 10 mM glycine pH 1.5
[0228] Determination: 10 min association à 10 min dissociation à 2x regeneration; flow rate: 10 μl / min
[0229] Evaluation was performed in the Biacore Insight Evaluation software, where kinetics and affinity fitting to sensorgrams (not shown) was performed. The K values for steady-state affinity were retrieved from the software. D and 1:1 kinetics.
[0230] Table 1. Protein L variants with the indicated amino acids at positions 10, 45 and 60, and KD values and 1:1 kinetics for steady state interactions. First, the table is sorted based on lowest steady state affinity KD. pAM114 is the wt B3 domain.
[0231]
[0232]
[0233] Example 2 - Alkaline stability of ligands - Biacore
[0234] The NaOH stability of the immobilized Protein L ligand was evaluated. The following assay conditions were used:
[0235] Analytes: Analytes were run in HBS-EP+ (Universal running buffer; 0.1 M HEPES, 1.5 M NaCl, 0.03 M EDTA and 0.5% v / v surfactant P20; from Cytiva TM )
[0236] Analyte concentration: 3.4 μM
[0237] Regeneration: 10 mM glycine pH 1.5
[0238] NaOH concentration: 100 mM
[0239] Determination: 10min analyte association à 1min analyte dissociation à 10min NaOH injection à 1min NaOH dissociation à 1min waiting à 2x regeneration à 1min waiting -> repeat 100 cycles. Flow rate: 10μl / min
[0240] Evaluation was performed in the Biacore Insight Evaluation Software, where responses were collected at the reporting point "Late Binding". Cycle 1 (priming) and cycle 2 (first cycle of analysis) were excluded from the evaluation. The response in the first evaluation cycle (cycle 3) was set to 100%, and responses in the subsequent 99 cycles were set to a percentage of the response in the first cycle.
[0241] Table 2. Protein L variants with the indicated amino acids, and percent binding capacity after 100 cycles of 0.1 M NaOH. First, the table is sorted based on the highest capacity after 100 cycles. pAM114 is the wt B3 domain.
[0242]
[0243]
[0244] The results show that all variants except pAM240 have better NaOH stability compared to pAM114 (wt B2 domain). The HHY variant seems to have slightly better NaOH stability compared to HHQ. However, in general, both variants perform well. NaOH stability is mainly domain dependent, with B5, C1, C2 and C3 showing the lowest alkali stability. For both variants HHY and HHQ, C3b, B3, C2b, B2, B4, C4 and D1 all show very good alkali stability.
[0245] It is clear from the above disclosed experiments that mutations N10H, N45H and N60Y or N60Q have a positive effect on the NaOH stability of protein L, and the affinity is maintained. Notably, the effect is shown on a wider range of protein L domains. In particular, the effect is shown for the B2 domain, the B3 domain, the B4 domain, the C2b domain, the C3b domain, the C4 domain and the D1 domain.
[0246] Separation matrix
[0247] For the prototype tested, ligand B2-1 (pAM237) corresponding to SEQ ID NO: 3 was used. The pentamer of SEQ ID NO: 3 was expressed and purified by conventional means known to those skilled in the art.
[0248] Example 3 - Coupling and filling
[0249] Purified pentamer of SEQ ID NO: 3 was immobilized on agarose beads as a base matrix according to the following exemplary method.
[0250] activation
[0251] The base matrix used was rigid cross-linked agarose beads having the indicated volume weighted median diameter, prepared according to the method of US6602990 and having the indicated pore size corresponding to a reverse phase gel filtration chromatography Kav value of 0.70 for dextran of Mw 110 kDa, according to the method described in Gel Filtration Principles and Methods, Pharmacia LKB Biotechnology 1991, pp. 6-13.
[0252] 25 mL (g) of drained base matrix, 10.0 mL of distilled water and 2.02 g of NaOH (s) were mixed in a 100 mL flask while mechanically stirring at 25° C. for 10 min. 4.0 mL of epichlorohydrin was added and the reaction was carried out for 2 hours. The activated gel was washed with 10 times the gel sedimentation volume (GV) of water.
[0253] Coupling
[0254] Sodium carbonate (0.01 M), sodium bicarbonate (0.1 M), sodium chloride (0.15 M) and EDTA disodium salt (1 mmol) were added to the protein aqueous solution, and when all dissolved, dithiothreitol (DTT, 0.1 M) was added. The pH was adjusted to above pH 8.0. The reaction mixture was placed on a shaker (23° C., 500 rpm) and allowed to reduce for 2 hours.
[0255] PD10 prepacked gel filtration column (Cytiva TM ) to desalt the protein. Before loading the protein (maximum 2.5 mL), the column was equilibrated with desalting solution (0.15 NaCl, 1 mM EDTA). The eluted fractions were collected and combined.
[0256] The protein concentration of the desalted solution was determined by UV absorbance at 276 nm, where the protein extinction coefficient is 1.0.
[0257] The activated gel was washed with 5GV 0.1M trisaminomethane (Tris) buffer pH 8.4. 15mL gel, 20mg ligand / mL gel (11.7mL), 3.3mL Tris buffer and 7.0g sodium sulfate were mixed in a 50mL flask and stirred at 33°C for 4h.
[0258] After immobilization, the gel was washed with 3×1GV distilled water. The gel was mixed with 1GV (0.1M phosphate / 1mM EDTA / 7.5% thioglycerol pH 8.5) and the flask was kept stirring at room temperature for 15-20h. The gel was then washed 3 times alternately with 3×1GV 0.5M HAc and 3×1GV 0.1M TRIS / 0.15M NaCl pH 8.5, followed by 10×1GV mL distilled water. The gel was conditioned in 20% EtOH in 50% slurry.
[0259] Determination of ligand density by amino acid analysis of AAA
[0260] All synthesized prototypes are dried and the dry weight is determined. Those skilled in the art are aware of the commonly known methods for carrying out such a procedure. The prototypes are then dried and sent for amino acid analysis. Using the corresponding dry weight and an Excel spreadsheet containing information on the size of the protein and all data on the primary amino acid sequence of the protein, the ligand density in mg ligand / mL resin can be derived.
[0261] Filling of separation matrix prototypes
[0262] Fill TRI CORN with 2 ml of resin TM 5 / 100 column (Cytiva TM )middle.
[0263] Example 4 - Dynamic Binding Capacity (DBC)
[0264] Preparation of trastuzumab samples
[0265] The Herceptin (trastuzumab) solution was diluted to 2 mg / mL. The concentration of the sample solution was determined by spectrophotometry (QS High Precision cell, Hellma Analytics) at 280 nm, using 1.48 mL / mg*cm as the absorbance coefficient in triplicate. The trastuzumab concentration was confirmed by online UV measurement at 280 nm in a 2 mm UV-cell in Unicorn 7.5.
[0266] Determination of 100% absorbance signal
[0267] PBS buffer was flowed through the bypass position until a stable baseline was achieved. Automatic zeroing was performed and trastuzumab solution was applied through the bypass to obtain a stable 100% signal, 6 min RT. The absorbance value was recorded. PBS buffer was flowed through the bypass position until a stable baseline was achieved.
[0268] DBC measurement
[0269] Adsorption / equilibrium buffer: phosphate buffer 20 mM + 0.15 M NaCl, pH 7.2
[0270] Elution buffer: Citrate buffer 50 mM, pH 2.5
[0271] CIP: 0.1M NaOH
[0272] via The trastuzumab sample was loaded onto the 2 ml column at the desired flow rate (depending on the residence time) using the S-pump (sample pump) on the pure 25M until the UV signal reached approximately 20% of the maximum value. The column was then washed with adsorption buffer at a flow rate of 1 mL / min. The protein was eluted with elution buffer at a flow rate of 0.8 mL / min.
[0273] The column was cleaned with the CIP protocol during 3CV with 15 min contact time, 0.1 M NaOH at a flow rate of 0.2 mL / min, followed by re-equilibration with adsorption buffer.The column was cleaned manually with 20% EtOH.
[0274] The penetration capacity is calculated using Extensions-DBC Calculations-Analyze, which is the same as pure 25M is an evaluation tool in the Unicorn software used together.
[0275] To calculate the breakthrough capacity at 10% (Qb10), the following equation was used. That is, this is the amount of trastuzumab loaded onto the column until the trastuzumab concentration in the column effluent is 10% of the trastuzumab concentration in the liquid sample.
[0276]
[0277] A 100% =100% UV signal
[0278] A sub = absorbance contribution from non-bound mAb
[0279] A(V) = absorbance at a given applied volume
[0280] V C = column volume
[0281] V app = Volume applied until 10% penetration
[0282] V sys = System dead volume
[0283] C0 = liquid sample concentration
[0284] Correspondingly, the breakthrough capacity at 80% (Qb80) is the amount of trastuzumab loaded onto the column until the trastuzumab concentration in the column effluent is 80% of the trastuzumab concentration in the liquid sample.
[0285] Table 3. DBC data of prototypes N1-N26 and P24, including the main factors DW, d50v and ligand density.
[0286]
[0287]
[0288] The choice of ligand density was further tested for alkaline stability.
[0289] Table 4. Residual capacity in the presence of trastuzumab for the indicated ligand densities
[0290] Ligand density Remaining capacity after 112 CIP cycles with 0.1M NaOH 15.5 96.2 11.9 85.2 17.8 100.5 19.0 99.0 14.6 96.4 16.9 99.8 16.1 93.4 10.4 82.5 20.4 102.6
[0291] The results of Table 4 are plotted on Figure 1a , where a clear correlation between ligand density and alkaline stability can be observed.
[0292] Additionally, the choice of ligand density was tested for DBC of 10% breakthrough of the Fab fragment at 6 min residence time.
[0293] Fab fragments are produced by papain cleavage from trastuzumab. The trastuzumab solution is adjusted to pH 7.4 by adding 0.5M sodium phosphate and then diluted 1+1 in digestion buffer (25mM sodium phosphate, 1mM EDTA, 5mM mercaptoethanol, pH7.5). The final volume is about 100mL. Papain crystals are added to the solution. The solution is incubated overnight at 37°C. Thereafter, antipapain (papain inhibitor) is added to the digested trastuzumab. The solution is kept at room temperature for 30min and then applied to Capto TM L HiScale 26 column to remove Fc-containing molecules (Fc or partially digested trastuzumab, collected in the flow-through). Fab was collected during elution.
[0294] Table 5. Residual capacity in the presence of Fab fragments for the indicated ligand densities
[0295] Ligand density DBC Qb10%6min RT 10.6 56.8 15.0 66.7 13.0 62.4 16.1 67.9 11.0 55.5 15.3 66.4
[0296] The results of Table 5 are plotted on Figure 1b , where a clear correlation between ligand density and DBC can again be observed.
[0297] Figure 2 The relationship of DBC to ligand density, Kd and Dw is shown. Clearly, the herein disclosed ranges for KD, d50V and ligand density of the alkali-stabilized protein L domains disclosed herein result in a favorable DBC.
[0298] Next, the choice of ligand density was tested specifically for alkaline stability.
[0299] Table 6. Testing of 5 prototypes with indicated ligand density and relative DBC.
[0300]
[0301]
[0302] like Figure 1c As can be seen in Figure 1, all prototypes showed a Qb10% higher than 80% after 112 CIP cycles. Specifically, prototypes with ligand densities falling within the range disclosed in the present invention showed a Qb10% higher than 90%. The worst performing prototype had a ligand density lower than 12 mg / ml.
[0303] Example 5 - Alkali Stability
[0304] DBC was tested for three different ligand densities (base matrix: KD 0.75, Dw 66.5 mg / ml and d50v 62.3 μm) and compared with two commercially available products during the CIP process.The antibody used in the test was trastuzumab.
[0305] Trastuzumab was diluted to 2 mg / mL. The concentration can be determined according to any method known in the art.
[0306] The indicated prototypes were included in accelerated alkaline stability studies to investigate how stability depends on ligand density. TM L is included as a reference. DBC Qb of trastuzumab at 4 min residence time measured between incubations in 100 mM NaOH 10% The data are presented in Table 5.
[0307] The stripping step was performed with 50 mM citrate pH 2.3, followed by equilibration (20 mM sodium phosphate + 150 mM NaCl pH 7.2) and then incubation in 100 mM NaOH. The incubation was performed for 4 hours, corresponding to 16 CIP cycles with 15 min contact time. The DBC Qb of trastuzumab at 4 min residence time was measured between incubation runs. 10% The dynamic binding capacity was measured with trastuzumab and the relative remaining capacity with respect to the initial DBC was calculated between incubations corresponding to a total of 100 CIP cycles.
[0308] Table 7. Ligand density tested relative to Capto TM L, DBC at different cycle numbers.
[0309]
[0310]
[0311] *Available from Cytiva TM Commercially available
[0312] The above results are shown in Figure 3a The same results recalculated as relative DBC are shown in Figure 3b In. At the beginning DBCQb 10% The values show that the prototype 17.7 mg / ml provides a lower capacity compared to the other prototypes at 14.2 mg / ml. However, the DBC Qb of the prototype 17.7 mg / ml 10% As the number of CIP cycles (i.e., incubation time in NaOH) increased, it showed better alkaline stability compared to the other prototypes at 14.2 mg / ml ( Figure 3a ).
[0313] To compare the separation matrices with respect to alkaline stability, Qb relative to the starting DBC was calculated with respect to the number of CIP cycles. 10% The relative residual DBC Qb 10% After 100 cycles (i.e., a total of 25 h incubation in 100 mM NaOH), all prototypes included in this study achieved more than 80% of the remaining capacity.
[0314] Therefore, it is clear that both prototypes tested with ligand densities of 14.2 mg / ml and 17.7 mg / ml have very good DBC after 100 cycles, showing a significant improvement over Capto TM LHigher DBC.
[0315] It was further tested whether the separation matrix according to the present disclosure could withstand cleaning at higher base concentrations than conventionally used for protein L separation matrices. As disclosed above, a Tricorn 5 / 50 column was packed with the prototype resin containing 17.7 mg / ml ligand.
[0316] 300mM NaOH
[0317] Using trastuzumab, the column was subjected to 15 min CIP with 300 mM NaOH / cycle. Determination of DBC Qb for 3 min residence time 10% . Experimental use pure 25M.
[0318] Equilibration: 20 mM sodium phosphate 150 mM NaCl pH 7.2, 1 ml / min, 5 CV
[0319] Sample loading: via sample pump, 0.333 ml / min (3 min RT) to 20% absorbance maximum)
[0320] Wash: 0 mM sodium phosphate 150 mM NaCl pH 7.2, 1 ml / min, 7 CV
[0321] Elution: 50 mM sodium citrate pH 2.5, 1 ml / min, 5 CV
[0322] Washing: Milli-Q water, 1 ml / min, 5 CV
[0323] CIP: 300 mM NaOH, 0.2 ml / min, 3 CV (15 min contact time)
[0324] Re-equilibration: 20 mM sodium phosphate 150 mM NaCl pH 7.2, 1 ml / min, 5 CV
[0325] Table 8. Results of 15 min CIP, 300 mM NaOH / cycle, 3 min RT with trastuzumab.
[0326] CIP cycle QB10 Relative remaining capacity% 0 52.3 100 10 51.9 99 20 52.6 100 30 53.7 103 40 54.7 105 50 56.6 108 60 56.9 109 70 57.5 110 80 57.1 109 90 56.0 107 100 54.1 103 110 49.9 96 120 50.0 96 130 46.5 89
[0327] 500mM NaOH
[0328] In the presence of trastuzumab, the column was subjected to 15 min CIP with 500 mM NaOH / cycle. The DBC Qb10% was determined for a 4 min residence time. pure 25M.
[0329] Equilibration: 20 mM sodium phosphate 150 mM NaCl pH 7.2, 1 ml / min, 5 CV
[0330] Sample loading: via sample pump, 0.25 ml / min (4 min RT) to 20% absorbance maximum)
[0331] Wash: 0 mM sodium phosphate 150 mM NaCl pH 7.2, 1 ml / min, 7 CV
[0332] Elution: 50 mM sodium citrate pH 2.5, 1 ml / min, 5 CV
[0333] Washing: Milli-Q water, 1 ml / min, 5 CV
[0334] CIP: 500 mM NaOH, 0.2 ml / min, 3 CV (15 min contact time)
[0335] Re-equilibration: 20 mM sodium phosphate 150 mM NaCl pH 7.2, 1 ml / min, 5 CV.
[0336] Table 9. Results of 15 min CIP, 500 mM NaOH / cycle, 4 min RT with trastuzumab.
[0337] CIP cycle QB10 Relative remaining capacity% 0 60.4 100 10 61.7 102 20 63.0 104 30* - - 40* - - 50 56 93 60 50 83 70 44 72
[0338] *Data not shown due to fault dwell time.
[0339] like Figure 3cAs can be seen in Figure 1, where the relative residual capacities of 0.1 M NaOH, 0.3 M NaOH, and 0.5 M NaOH are plotted, the separation matrix of the present disclosure also has excellent alkaline stability for higher alkaline concentrations. For 0.1 M NaOH, the separation matrix has 90% residual capacity after 200 cycles. For 0.3 M NaOH, the separation matrix has about 90% residual capacity after 130 cycles, and for 0.5 M NaOH, the separation matrix has about 90% residual capacity after 50 cycles.
[0340] Example 6 - Comparative Test - DBC
[0341] Next, the DBC Qb values of adalimumab, Fab, dAb, and trastuzumab at 1, 2.4, 4, 6, and 10 min residence times were measured for the prototype (ligand density of about 14.3 mg / ml, KD of about 0.75, Dw of about 66.5 mg / ml, and d50v of about 62.3 μm). 10% .
[0342] Fab was produced as disclosed above. dAb was prepared according to the article “Recombinant production of a V L The antibody was produced by the method described in "singledomain antibody in Escherichia coli and analysis of its interaction with Peptostreptococcal protein L" (Protein Expression and Purification, Vol. 51, No. 2, February 2007, pp. 253-259).
[0343] With DBC Qb 10% The data are presented in Table 10.
[0344] Table 10.
[0345]
[0346] The results showed that the DBC Qb of Fab 10% The optimal value was achieved from 6 min and longer residence time, while the DBCQb of mAb 10% It is possible that this may be further increased with longer residence time. The kinetics of dAbs are very fast and for the prototype, the DBC Qb of the smaller fragments 10% The optimal residence time was 2.4 min.
[0347] The prototype resin was then compared to three commercially available Protein L resins. The prototype resin was packed in triplicate in a Tricorn 5 / 100 column and DBC was performed according to the method described above. AF-rProtein L-650F(Tosoh)、KanCap TM L(KaneKa) and Capto TM L(Cytiva TM ), DBC Qb10% was determined with antibodies or antibody fragments at the indicated retention times. The average of the data from triplicate columns is presented below.
[0348] Table 11. DBC of trastuzumab at different residence times
[0349]
[0350]
[0351] * AF-r Protein L-650F
[0352] Figure 4a The results shown show that for a residence time of 1 min, the prototype performs slightly better than Capto TM L and KanCap TM L, and AF-r Protein L-650F showed a higher capacity. However, for a residence time of 2.4 min, the prototype and AF-r Protein L-650F was comparable and for residence times of 6, 8 and 10 min, the prototype showed AF-r Protein L-650F has significantly higher DBCQb 10% .
[0353] With Capto TM Compared with L, for longer residence times (6-10 min), the prototype exhibited twice as high DBCQb 10% .
[0354] DBC was also determined according to the above method with Fab fragments at the indicated retention times on duplicate columns with the indicated resins.
[0355] Table 12. For prototype, AF-r Protein L-650F(Tosoh)、Capto TM L(Cytiva TM ) and KanCap TML (KaneKa), DBC Qb10% DBC of Fab fragments at different residence times.
[0356] Resin 1min 2.4min 4min 6min 10min <![CDATA[Capto TM L]]> 16.9 19.4 20.4 20.5 20.9 <![CDATA[KanCap TM L]]> 32.0 41.5 44.0 46.0 46.8 TOYOPEARL* 43.7 53.2 56.2 57.7 58.1 prototype 48.1 62.2 66.4 68.8 69,7
[0357] * AF-r Protein L-650F
[0358] The results show that AF-r Protein L-650F and KanCap TM L compared with Capto TM The prototype has significantly better DBC Qb for Fab at all residence times compared to L 10% , see Figure 4b .
[0359] In addition, DBC was determined using the dAbs at the indicated retention times according to the method described above on duplicate columns with the indicated resins.
[0360] Table 13. For prototype, TOYOPEARL (Tosoh) and Capto TM L(Cytiva TM ), DBC Qb10% DBC of dAb at different residence times.
[0361] Resin 2.4min 4min 6min 10min <![CDATA[Capto TM L]]> 15.8 16.2 16.4 16.7 TOYOPEARL* 23.7 25.2 26.3 26.0 prototype 37.0 37.9 38.7 40.0
[0362] * AF-r Protein L-650F
[0363] Likewise, the results show that AF-r Protein L-650F compared with Capto TM The prototype also had significantly better DBC Qb for dAb at all residence times compared to L 10% , see Figure 4c .
[0364] Example 7 - Isolation of bispecific antibodies
[0365] The ability to separate bispecific antibodies from monospecific antibodies based on the kappa light chain was tested. In this experiment the separation matrix as in the previous examples was used, packed in a Tricorn 5 / 100 column.
[0366] The Ab-containing liquid sample (bsAb01) tested in this experiment is a sample commercially available from Thermo Fisher, which contains a) κ light chain, trastuzumab κ1 class anti-HER2 light chain (1 and 2); b) λ-light chain, avelumab λ2 class anti-PDL1 light chain; and c) FC chain, anti-HER2 heavy chain (1 and 2). They are present in the sample at a ratio of 30:30:40, respectively.
[0367] The pH is gradually reduced during elution.
[0368] Table 14. Materials used for step elution.
[0369]
[0370] Liquid samples were prepared by thawing at room temperature and filtered through a 0.2 μm filter. Based on peak integration, the concentration of mAb in the liquid samples was estimated to be approximately 0.1 mg / ml.
[0371] After column equilibration with equilibration buffer, 50 ml of liquid sample was applied to the 1 ml column at 0.250 ml / min, followed by 10 CV of wash buffer.
[0372] Step elution was performed by first applying 5CV of pH 3.4 elution buffer 1, followed by 5CV of pH 3.1 elution buffer 2 at a flow rate of 1.0 ml / min. After elution, a 3CV pH 2.3 stripping step was performed, followed by a 3CV 0.1M NaOH CIP step. Fractions were collected using peak fractionation. The results are shown in Figure 5a This step was repeated, wherein the elution volume was changed to 10CV. The results are shown in Table 5b.
[0373] like Figure 5a As can be seen in the figure, in the initial 5CV elution volume run, three distinct peaks can be observed with some tailing and overlap between the main peaks. An initial small peak eluting at pH 4.45 is also observed.
[0374] At 10 CV elution volume, baseline separation of κλ-heterodimer and κκ-homodimer was achieved, as shown in Figure 5b As seen in.
[0375] Fractions of full-length and reduced forms from the 10 CV run were analyzed by mass spectrometry (MS). Figure 5b In the Figures, these fractions are marked with *.
[0376] Unreduced MS results from fraction 1 ( Figure 5bPeak 1 in indicates that it is similar to full-length mAb (data not shown). When the sample is reduced, multiple peaks corresponding to the triple light chain peak are resolved, and the FC peak and unknown peak are observed (data not shown). The observed light chain has the same mass as the mass observed for the λ light chain of κλ-dimer. FC has the same mass as the mass observed for κλ and κκ dimers. This λλ-dimer is very easy to elute at pH 4.45 and may be removed or separated by increased resin washing after the sample is applied or the initial pH gradient is not too steep.
[0377] Figure 5b Peak 2 in is a bispecific κλ mAb, see Figure 6a , with a total length of 147406 Da. When reduced, two types of light chains can be observed (data not shown).
[0378] Figure 5b Peak 3 in is the κκ-homodimer, see Figure 6b , where a small fraction of free κ-light chains was observed. In the reduced MS data (data not shown), only one type of light chain was observed, the size of which corresponds to the size of the κ-light chain observed for the κλ-bispecific mAb.
[0379] Thus, a stepwise pH separation of bispecific kappa light chain-containing monoclonal antibodies is possible using the separation matrix according to the invention. By simply adjusting the elution volume at each pH baseline, separation of bispecific heterodimers and homodimers can be achieved.
[0380] Elution with pH gradient
[0381] Table 15. Materials used for gradient elution
[0382]
[0383] Adsorption / equilibrium buffer: phosphate buffer 20 mM + 0.15 M NaCl, pH 7.2
[0384] Elution buffer: 50 mM citrate buffer, pH 5.5, 50 mM citrate buffer, pH 2.5
[0385] Stripping buffer: 50 mM citrate, pH 2.3
[0386] CIP: 0.1M NaOH
[0387] After equilibration, approximately 100 ml of BsAb_mAb01 sample was loaded into a 1 ml column via a B-pump at a desired flow rate of 0.25 ml / min. The column was then washed with 10 CV of wash buffer at a flow rate of 1 mL / min. The protein was eluted over 40 CV with a pH gradient of 50 mM citrate pH 5.5-2.5 at a flow rate of 0.25 ml / min.
[0388] The column was cleaned using 50 mM citrate pH 2.3, followed by stripping with 0.1 M NaOH at a flow rate of 0.4 mL / min, and finally re-equilibrated with 10 CV of adsorption buffer.
[0389] The elution was collected by peak fractionation starting at 50 mAu.
[0390] The bound fraction eluted as two major peaks A and B at pH 3.36 and pH 3.12, see Figure 7 Presumably, these peaks are associated with the bispecific κλ-heterodimer, which elutes first at pH 3.26, and the κκ-homodimer, which elutes later at pH 3.12. The λλ-homodimer does not bind and does not elute during the gradient.
[0391] like Figure 7 As indicated, samples from fractions A6 and B4 were also reduced and then analyzed by MS (data not shown). This analysis clearly showed that A6 was composed of κ-light chain (23439 Da), λ-light chain (22785 Da) and FC chain (25297 Da). It was shown that B4 was composed of only κ-light chain (23439 Da) and FC chain (25297 Da).
[0392] Thus, the above examples show that the separation matrix according to the appended claims has improved alkaline stability and a DBC of 10% breakthrough for all antibodies or antibody fragments tested compared to similar commercially available products.
[0393] This written description uses examples to disclose the invention and also enables any person skilled in the art to practice the invention. The patentable scope of the invention is defined by the claims and may include other embodiments that occur to those skilled in the art. Such other embodiments are intended to be within the scope of the claims if they have structural elements that are not different from the literal language of the claims, or if they include equivalent structural elements that are not significantly different from the literal language of the claims. Any patent or patent application mentioned in the text is incorporated herein by reference in its entirety as if they were incorporated individually.
Claims
1. A separation matrix comprising at least 12 mg / ml of a κ light chain binding ligand covalently coupled to a porous carrier, wherein The kappa light chain binding ligand comprises, consists essentially of, or consists of a multimer of alkali-stable Peptostreptococcus magna (formerly known as Peptostreptococcus magna) protein L domains; and The porous carrier comprises polymer particles having a dry solid weight (D W ), volume-weighted median diameter (D50v) of 30-100 μm.
2. The separation matrix of claim 1, wherein the matrix comprises at least 14 mg / ml κ light chain binding ligand, such as at least 14.5 mg / ml, at least 15 mg / ml, at least 15.5 mg / ml, at least 16 mg / ml, at least 16.5 mg / ml, at least 17 mg / ml, at least 17.5 mg / ml, at least 18 mg / ml, at least 18.5 mg / ml or at least 19 mg / ml κ light chain binding ligand.
3. The separation matrix according to any one of claims 1 or 2, wherein the D of the porous carrier is W It is 50-150 mg / ml, 50-120 mg / ml, 50-100 mg / ml, 50-90 mg / ml, 60-80 mg / ml or 60-75 mg / ml, such as at least 63 mg / ml, or at least 65 mg / ml, or at least 70 mg / ml.
4. A separation matrix according to any of the preceding claims, wherein the volume weighted median diameter (D50v) of the porous support is 35-90 μm, 40-80 μm, 50-70 μm, 55-70 μm, 55-67 μm, 58-70 μm or 58-67 μm, such as at least 60 μm or at least 62 μm.
5. The separation matrix according to claim 4, having a Kd value of 0.6-0.95, such as a Kd value of 0.7-0.9, or a Kd value of 0.6-0.8, such as a Kd value of about 0.67, or a Kd value of about 0.72, or a Kd value of about 0.75, measured by reversed phase size exclusion chromatography using dextran with a Mw of 110 kDa as probe molecule.
6. The separation matrix according to any one of the preceding claims, wherein the polymer particles are cross-linked.
7. The separation matrix according to any of the preceding claims, wherein at least two of the alkali-stable protein L domains are selected from the group consisting of functional variants of the B1 domain, B2 domain, B3 domain, B4 domain, B5 domain, C2 domain, C3 domain, C4 domain and D1 domain of protein L of Peptostreptococcus magna (formerly known as Peptostreptococcus magna), wherein the positions corresponding to positions 10 and 45 in the B2 domain (SEQ ID NO 1) in the alignment are histidine, and the position corresponding to position 60 in the B2 domain (SEQ ID NO 1) in the alignment is tyrosine or glutamine.
8. The separation matrix according to claim 7, wherein the at least two alkali-stable protein L domains are selected from the group consisting of a B2 domain, a B3 domain, a B4 domain, a C2 domain, a C3 domain, a C4 domain and a D1 domain.
9. The separation matrix according to claim 7 or 8, wherein the at least two alkali-stable protein L domains have at least 90%, 95% or 98% sequence identity or 77.5% sequence similarity with any of the amino acid sequences SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18 or SEQ ID NO 19 as determined by a BLOSUM matrix of 75, wherein the gap opening penalty is 12 and the gap extension penalty is 3, wherein the positions corresponding to positions 10 and 45 in the alignment and the position corresponding to position 60 in the alignment are invariant.
10. The separation matrix according to any one of the preceding claims, wherein the separation matrix comprises three, four, five, six, seven, eight or nine alkali-stable protein L domains.
11. The separation matrix according to claim 10, wherein the separation matrix comprises four, five or six alkali-stable protein L domains.
12. The separation matrix according to any one of the preceding claims, wherein the ligand comprises a coupling element which is one or more cysteine residues, one or more lysine residues, or one or more histidine residues at the C-terminus of the ligand.
13. The separation matrix of claim 12, wherein the ligand comprises one or more cysteine residues at the C-terminus of the ligand.
14. The separation matrix according to any one of claims 1 to 13, wherein the separation matrix has a 10% breakthrough dynamic binding capacity for IgG of at least 55 mg / ml at a residence time of 4 min.
15. The separation matrix according to any one of claims 1 to 14, wherein the separation matrix has a 10% breakthrough dynamic binding capacity for IgG of at least 70 mg / ml at a residence time of 6 min.
16. The separation matrix according to any one of claims 1 to 15, wherein the separation matrix has a 10% breakthrough dynamic binding capacity for IgG of at least 80 mg / ml at a residence time of 10 min.
17. The separation matrix according to any one of claims 1 to 16, wherein the IgG capacity of the separation matrix after incubation in 0.1 M NaOH at 22+ / -2°C for 24 h is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before the incubation.
18. The separation matrix according to any one of claims 1 to 16, wherein the IgG capacity of the separation matrix after incubation in 0.3 M NaOH at 22 + / - 2°C for 32 h is at least 90% of the IgG capacity before the incubation.
19. The separation matrix according to any one of claims 1 to 16, wherein the IgG capacity of the separation matrix after incubation in 0.5 M NaOH at 22 + / - 2°C for 12 h is at least 95%, or at least 93% of the IgG capacity before the incubation.
20. A method for isolating a protein containing a kappa light chain, the method comprising: The following steps are involved: a) contacting a liquid sample comprising a protein containing a kappa light chain with a separation matrix; b) washing the separation matrix with a washing liquid or a combination of washing liquids; c) eluting the κ light chain-containing protein from the separation matrix using an eluent; and d) cleaning the separation matrix with a cleaning solution; wherein the IgG capacity of the separation matrix after incubation in 0.1 M NaOH at 22+ / -2°C for 24 h is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before the incubation.
21. A method for isolating a bispecific antibody, the method comprising: The following steps are involved: a) contacting a liquid sample comprising a protein containing a kappa light chain with a separation matrix, b) washing the separation matrix with a washing liquid or a combination of washing liquids, c) eluting the kappa light chain-containing protein from the separation matrix using an eluent and at a reduced pH, d) cleaning the separation matrix with a cleaning solution, wherein the IgG capacity of the separation matrix after incubation in 0.1 M NaOH at 22+ / -2°C for 24 h is at least 80%, or at least 85%, or at least 90%, or at least 95% of the IgG capacity before the incubation.
22. The method according to claim 21, wherein lowering the pH is performed by using a pH gradient.
23. The method of claim 21, wherein lowering the pH is performed in a stepwise manner.
24. The method of any one of claims 21-23, wherein the lowered pH is about 5.5 to about 2, such as about 5 to about 2, about 4.5 to about 2, or about 4 to about 2.
25. The method of any one of claims 20-24, wherein the cleaning solution comprises 0.01-1.0 M NaOH or KOH, such as 0.05-1.0 M or 0.05-0.1 M, or 0.05-0.3 M, or 0.05-0.5 NaOH or KOH.
26. The method according to any one of claims 20 to 25, wherein the eluent comprises at least one anionic species selected from the group consisting of acetate, citrate, glycine, succinate, phosphate and formate.
27. The method according to any one of claims 20 to 26, wherein steps a) to d) are repeated at least 10 times, such as at least 50 times or 50-200 times.
28. The method according to any one of claims 20-27, wherein the separation matrix is according to any one of claims 1-19.
29. A chromatography column comprising the separation matrix according to any one of claims 1-19.
30. Use of a chromatography column according to claim 29 in a method according to any one of claims 20-28.
Citation Information
Patent Citations
Process for the production of a porous cross-linked polysaccharide gel and its use as a gel filtration media and in chromatography
US6602990B1
Protein L and hybrid proteins thereof
US6822075B2
Method of preparing a chromatography matrix
US7396467B2
